

GREVIANCE REPORT FOR HEPATITIS B & C MEDICINES FOR HEPATITIS CONTROL PROGRAM PUNJAB

“MINUTES OF THE MEETING OF THE GRIEVANCE REDRESSAL COMMITTEE”



DATED: 14TH SEPTEMBER, 2022

**HEPATITIS CONTROL PROGRAM PUNJAB
PRIMARY & SECONDARY HEALTHCARE DEPARTMENT
GOVERNMENT OF PUNJAB**

BID REFERENCE NO: 01/HCP/MED/07/2022

MINUTES OF THE MEETING OF THE GRIEVANCE REDRESSAL COMMITTEE HELD ON 14th SEPTEMBER, 2022 AT 04:00 P.M TO ADDRESS THE GREVIANCES OF THE BIDDER AS PER RULES 67 PUNJAB PROCUREMENT RULES, 2014 AGAINST TECHNICAL EVALUATION FOR MEDICINE FOR HEPATITIS CONTROL PROGRAM PUNJAB.

1. A meeting of the Grievance Redressal committee was held on 14th September, 2022 at 04:00 P.M in the office of Additional Secretary (Vertical Programs) of Primary & Secondary Healthcare Department Lahore, to address the grievance of the Bidders as per rule 67 of Punjab Procurement Rules 2014, against the Technical Evaluation of Medicines. Additional Secretary (Vertical Program) chaired the meeting.

2. Following attended the meeting:

- a. Additional Secretary (Vertical Programs) In Chair
Primary & Secondary Healthcare Department (P&SHD)
- b. Deputy Program Manager-I Member
Hepatitis & Infection Control Program, DGHS Punjab
- c. Program Officer-II Member
Hepatitis & Infection Control Program, DGHS Punjab

3. The case wise proceedings of the meetings will be as follows:

Sr #	AGGRIEVED BIDDER NAME	NAME OF THE ITEM	GREVIANCE OF THE APPLICANT	DELIBERATIONS & DECISION BY GRIEVANCE REDRESSAL COMMITTEE
1	M/S AGP PHARMA	Sofosbuvir 400 mg	Quoted Product must have WHO prequalification /JpMHLW/ EMA / US FDA Approval. The WHO prequalification provided by the firm in the technical bid was expired. In response to the technical evaluation uploaded the firm submitted the Who prequalification report of the quoted product issued on 20.07.2017. the firm also submitted the WHO assessment report of the	The firm has provided the valid WHO Prequalification report of the product. After due deliberations and discussion, the committee unanimously accepted the grievance of the firm.

			<p>finished product manufacturing plant with the date of assessment 09.04.2021.</p> <p>The firm requested to accept the required documents and considered their application as responsive.</p>	<p>Hence declaring the Status of the firm as RESPONSIVE for the item Sofosbuvir 400 mg.</p>
2	M/S GENIX	Sofosbuvir 400 mg	<p>The firm was not Responsive in the Technical Evaluation Report (Part-II). The Documents for the documented proof of pharmacists was not upto mark. In response to the technical evaluation uploaded the firm provided the details of 45 Pharmacists and attached the documented verifications of 15-17 of Pharmacists.</p> <p>The firm requested to accept the required documents and considered their application as responsive.</p>	<p>The firm has provided the documented proof of required number of pharmacists. After due deliberations and discussion, the committee unanimously accepted the grievance of the firm and awarded the 05 numbers of Point No 09 accumulating the total to 45 in TER part-II.</p> <p>Hence declaring the Status of the firm as RESPONSIVE for the item Sofosbuvir 400 mg.</p>
3	M/S GENIX	Daclatsavir 60 mg	<p>The firm was not Responsive in the Technical Evaluation Report (Part-II). The Documents for the documented proof of pharmacists was not upto mark. In response to the technical evaluation uploaded the firm provided the details of 45 Pharmacists and attached the documented verifications of 15-17 of Pharmacists.</p> <p>The firm requested to accept the required documents and considered their application as responsive.</p>	<p>The firm has provided the documented proof of required number of pharmacists. After due deliberations and discussion, the committee unanimously accepted the grievance of the firm and awarded the 05 numbers of Point No 09 accumulating the total to 45 in TER part-II.</p> <p>Hence declaring the Status of the firm as RESPONSIVE for the item Daclatsavir 60 mg.</p>

4. Meeting ended with the vote of thanks by chair